Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Arcus Biosciences, Inc. roe for the quarter ending 2026-06-30 was -99.14%, a change of -44.86% year-over-year.
Arcus Biosciences, Inc. roe for the quarter ending 2026-03-31 was -70.42%, a change of 3.21% year-over-year.
Arcus Biosciences, Inc. roe for the quarter ending 2025-12-31 was -55.94%, a change of 2.41% year-over-year.
Arcus Biosciences, Inc. roe for the quarter ending 2025-09-30 was -78.21%, a change of -30.42% year-over-year.
Arcus Biosciences, Inc. roe for fiscal 2025 was -55.94%, a change of 2.41% from fiscal 2024.
Arcus Biosciences, Inc. roe for fiscal 2024 was -58.35%, a change of 8.10% from fiscal 2023.
Arcus Biosciences, Inc. roe for fiscal 2023 was -66.45%, a change of -25.81% from fiscal 2022.
Arcus Biosciences, Inc. roe for fiscal 2022 was -40.64%, a 745.63% decline from fiscal 2021.